Tag - PTIX

Developments

Protagenic receives FDA pre-IND feedback for neuropeptide in GAD

Protagenic Therapeutics (OTCQB: PTIX) has announced that it has received written responses from the FDA to its Type B pre-Investigational New Drug (pre-IND) meeting request for PT00114, the company’s leading...

August 20, 2026

Markets

Maxim starts Protagenic Therapeutics at buy; PT $4

Maxim Group initiated coverage of Protagenic Therapeutics (NASDAQ:PTIX) with a “buy” rating and price target of $4. The stock closed at $1.80 on Oct. 28. Protagenic is developing its lead asset, PT00114, for the...

October 29, 2021

Tag - PTIX

Protagenic receives FDA pre-IND feedback for neuropeptide in GAD

Maxim starts Protagenic Therapeutics at buy; PT $4

Subscribe